STOCK TITAN

Engage with Pluri's Talent: Exciting Conference Appearances Ahead

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Pluri Inc. announces participation in key biotech conferences to showcase its innovative solutions for global wellbeing and sustainability.
Positive
  • None.
Negative
  • None.

HAIFA, Israel, March 19, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq:PLUR) (TASE:PLUR) ("Pluri" or "the Company"), a leading biotechnology company that transforms cells into solutions that promote global wellbeing and sustainability, today announced its participation in the following upcoming conferences.   

Conference: Bio-Europe Spring
Date: March 18-20, 2024
Location: Barcelona
Pluri’s Chief Business Development Officer-Pharma Efrat Kaduri will attend the event.
BIO-Europe Spring connects the global biopharma community to elevate life science partnerships, bringing together over 3,700 attendees from 2,000+ companies to engage in 20,000 one-on-one meetings.

Conference: Advanced Therapies 2024
Date: March 19-20, 2024
Location: London
Pluri’s Chief Technology Officer Lior Raviv will participate in a panel discussion titled: Points to consider when building supply chain operations from scratch on Tuesday, March 19, 2024 at 1:40 PM.
He will also give a presentation titled: Unleashing the Allogeneic Potential by Using Large Scale Automated Manufacturing Platforms on Wednesday, March 20, 2024 at 2:40 PM.
Pluri’s Chief Commercial Officer PluriCDMO Andy Lewin will attend the event.  
The Advanced Therapies congress is Europe’s largest cell and gene therapy conference and exhibition. The event brings together the world leaders in advanced therapy medicinal product development and the most senior executives in charge of the latest tech and strategies that are driving the industry forward.

Conference: CISH Impact Investments Holdings Conference
Date: March 28, 2024
Location: Online Event
Pluri’s Chief Executive Officer & President Yaky Yanay will be presenting at the conference on Thursday, March 28, 2024 at 2:20 PM.
CISH Impact Investments Holdings Conference is a global event on impact opportunities and investments in promising technology companies that have a positive impact on the community and the environment.

Meetings with the Pluri team can be scheduled via the various conference partnering engines or via email at info@pluri-biotech.com

About Pluri

Pluri is pushing the boundaries of science and engineering to create cell-based products for commercial use and is pioneering a biotech revolution that promotes global wellbeing and sustainability. The Company’s technology platform, a patented and validated state-of-the-art 3D cell expansion system, advances novel cell-based solutions for a range of initiatives— from medicine and climate change to food scarcity, animal cruelty and beyond. Pluri’s method is uniquely accurate, scalable, cost-effective, and consistent from batch to batch. Pluri currently operates in the field of regenerative medicine, food-tech and agtech and aims to establish partnerships that leverage the Company’s 3D cell-based technology to additional industries that require effective, mass cell production. Pluri also offers CDMO services. To learn more, visit us at http://www.pluri-biotech.com or follow us on LinkedIn and X. 

Media Contacts

Investors: investor.relations@pluri-biotech.com

Israel Media: Shachar Yental at Shacharye@gitam.co.il

U.S. Media: Madeline Weirman at Maddie@quantum-corp.com/ Jessica Daitch at Jessica@quantum-corp.com


FAQ

When is Pluri Inc. participating in the Bio-Europe Spring conference?

Pluri Inc. is participating in the Bio-Europe Spring conference from March 18-20, 2024, in Barcelona.

Who will represent Pluri Inc. at the Advanced Therapies 2024 conference?

Pluri Inc.'s Chief Technology Officer Lior Raviv will participate in a panel discussion and give a presentation at the Advanced Therapies 2024 conference in London on March 19-20, 2024.

What is the focus of the panel discussion at the Advanced Therapies 2024 conference?

The panel discussion at the Advanced Therapies 2024 conference will focus on building supply chain operations from scratch.

Who will be presenting at the CISH Impact Investments Holdings Conference?

Pluri Inc.'s Chief Executive Officer & President Yaky Yanay will be presenting at the CISH Impact Investments Holdings Conference on March 28, 2024, in an online event.

What is the theme of the CISH Impact Investments Holdings Conference?

The CISH Impact Investments Holdings Conference focuses on impact opportunities and investments in technology companies with a positive impact on the community and the environment.

Pluri Inc.

NASDAQ:PLUR

PLUR Rankings

PLUR Latest News

PLUR Stock Data

32.87M
3.16M
24.62%
10.7%
0.25%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
HAIFA

About PLUR

pluristem therapeutics inc. (nasdaqcm: psti, tase: psti/pltr) is a clinical-stage biotherapy company using placental cells and a unique, proprietary, three-dimensional (3d) technology platform to develop cell therapies for conditions such as inflammation, ischemia, hematological disorders, or exposure to radiation. pluristem’s placental expanded (plx) cells are placenta-derived, mesenchymal-like adherent stromal cells that are designed to be administered to patients without the need for tissue or genetic matching. these cells release soluble biomolecules, such as cytokines, chemokines and growth factors, which act in a paracrine or endocrine manner to facilitate healing of damaged tissues by stimulating the body’s own regenerative mechanisms. the company’s proprietary, 3d expansion technology can be used to grow plx cells in mass quantities with batch-to-batch consistency at pluristem’s fda, ema and pmda-approved, state-of-the art manufacturing facility. pluristem’s first product candi